Fungal Nail Infections (Onychomycosis): A Never-Ending Story?

1. HavlickovaA, CzaikaVA, FriedrichM (2008) Epidemiological trends in skin mycoses worldwide. Mycoses 51 S4: 2–15.

2. HanekeE, RoseeuwD (1999) The scope of onychomycosis: epidemiology and clinical features. Int J Dermatol 38 Suppl 2: 7–12.

3. OgasawaraY (2003) Prevalence and patient's consciousness of tinea pedis and onychomycosis. Nihon Ishinkin Gakkai Zasshi 44: 253–260.

4. GhannoumMA, HajjehRA, ScherR, KonnikovN, GuptaAK, et al. (2000) A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J Am Acad Dermatol 43: 641–648.

5. ScherRK (1994) Onychomycosis is more than a cosmetic problem. Br J Dermatol 130: 15.

6. GuptaAK, JainHC, LyndeCW, MacDonaldP, CooperEA, et al. (2000) Prevalence and epidemiology of onychomycosis in patients visiting physicians' offices: a multicenter Canadian survey of 15,000 patients. J Am Acad Dermatol 43: 244–248.

7. FaergemannJ, CorreiaO, NowickiR, RoBI (2005) Genetic predisposition - understanding underlying mechanisms of onychomycosis. J Eur Acad Dermatol Venerol 19: 17–19.

8. LanternierF, PathanS, VincentQB, LiuL, CypowyjS, etal (2013) Deep dermatophytosis and inherited CARD9 deficiency. N Engl J Med 369: 1704–1714.

9. SaunteDM, HolgersenJB, HaedersdalM, StraussG, BitschM, et al. (2006) Prevalence of toe nail onychomycosis in diabetic patients. Acta Derm Venerol 86: 425–428.

10. NenoffP, Ginter-HanselmayerG, TietzHJ (2012) Fungal nail infections - an update: Part 1 - Prevalence, epidemiology, predisposing conditions, and differential diagnosis. Hautarzt 63: 30–38.

11. ScherRK, BaranR (2003) Onychomycosis in clinical practice: factors contributing to recurrence. Br J Dermatol 149: 5–9.

12. ArreseJE, Pierard-FranchimontC, PierardGE (1996) Fatal hyalohyphomycosis following Fusarium onychomycosis in an immunocompromised patient. Am J Dermatopathol 18: 196–198.

13. AlyR (1994) Ecology and epidemiology of dermatophyte infections. J Am Acad Dermatol 31: S21.

14. GhannoumMA, MukherjeePK, WarshawEM, EvansS, KormanNJ, et al. (2013) Molecular analysis of dermatophytes suggest spread of infection among household members. Cutis 91: 237–246.

15. ElewskiB, TavakkolA (2005) Safety and tolerability of oral antifungal agents in the treatment of fungal nail disease: a proven reality. Ther Clin Risk Manag 1: 299–306.

16. TostiA, PiracciniBM, LorenziS (2000) Onychomycosis caused by nondermatophyte molds: clinical features and response to treatment of 59 cases. J Am Acad Dermatol 42: 217–224.

17. BlueCross BlueShield of Northeastern New York (2006 November 28) Drug Therapy Guidelines: Antifungal Agents Lamisil (terbinafine), Sporanox (itraconazole), Penlac (ciclopirox), Vfend (voriconazole). Drug P&T Newsletter.

18. LauharantaJ (1992) Comparative efficacy and safety of amorolfine nail lacquer 2% versus 5% once weekly. Clin Exp Dermatol 17: 41–43.

19. GhannoumMA, LongL, PfisterWR (2009) Determination of the efficacy of terbinafine hydrochloride nail solution in the topical treatment of dermatophytosis in a guinea pig model. Mycoses 52: 35–43.

20. FaergemannJ, ZehenderH, MilleriouxL (1994) Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails and after 250 mg terbinafine orally once daily for 7 and 14 days. Clin Exp Dermatol 19: 121–126.

21. OsborneCS, LeitnerI, FavreB, RyderNS (2004) Antifungal drug response in an in vitro model of dermatophyte nail infection. Med Mycol 42: 159–163.

22. GhannoumM, IshamN, HerbertJ, HenryW, YurdakulS (2011) Activity of TDT 067 (Terbinafine in Transfersome) against Agents of Onychomycosis, as Determined by Minimum Inhibitory and Fungicidal Concentrations. J Clin Microbiol 49: 1716–1720.

23. AlleyMR, BakerSJ, BeutnerKR, PlattnerJ (2007) Recent progress on the topical therapy of onychomycosis. Expert Opin Investig Drugs 16: 157–167.

24. GhannoumM, IshamN, CatalanoV (2013) A Second Look at Efficacy Criteria for Onychomycosis: Clinical and Mycological Cure. Br J Dermatol. E-pub ahead of print. doi:10.1111/bjd.12594

25. GuptaAK, SimpsonFC (2013) Laser therapy for onychomycosis. J Cutan Med Surg 17: 301–307.

26. HarrisF, PierpointL (2012) Photodynamic therapy based on 5-aminolevulinic acid and its use as an antimicrobial agent. Med Res Rev 32: 1292–1327.

27. Delgado-CharroMB (2012) Iontophoretic drug delivery across the nail. Expert Opin Drug Deliv 9: 91–103.

28. SilvaJL, DoimoG, FariaDP (2011) The use of high frequency waves to treat onychomycosis: preliminary communication of three cases. An Bras Dermatol 86: 598–600.

29. AbadiD, ZdericV (2011) Ultrasound-mediated nail drug delivery system. J Ultrasound Med 30: 1723–1730.

30. YazdanparastSA, BartonRC (2006) Arthroconidia production in Trichophyton rubrum and a new ex vivo model of onychomycosis. J Med Microbiol 55: 1577–1581.

31. BradleyM, LeidichS, IshamN, ElewskiB, GhannoumM (1999) Antifungal susceptibilities and genetic relatedness of serial Trichophyton rubrum isolates from patients with onychomycosis of the toenail. Mycoses 42: 105–110.

32. GhannoumMA, IshamN, LongL (2012) Optimization of an infected shoe model for the evaluation of an ultraviolet shoe sanitizer device. J Am Podiatr Med Assoc 102: 309–313.